Real world results with IN.PACT Admiral drug-coated balloon show benefits in peripheral arterial disease- Medtronic

Medtronic presented new data supporting the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The real-world outcomes from regional cohorts of the IN.PACT Global Study in Asia and Belgium reinforce the strong efficacy and consistent outcomes of the IN.PACT Admiral DCB across multiple patient populations.

One-year results from the Asian subset of the IN.PACT Global Study, including data from 114 patients at six sites in South Korea and Singapore continue to underscore the positive performance in both safety and efficacy for the IN.PACT Admiral DCB in a broader set of complex patients with PAD. In this subset analysis, the low clinically-driven target lesion revascularization (CD-TLR) at one year (3.8 percent) was consistent with the results in the complete cohort of 1,406 patients in the IN.PACT Global Study (7.5 percent). Results of the primary safety endpoint in the Asian cohort were also consistent with results from the full Global Study cohort, with 96.2 percent of patients achieving positive outcomes.

IN.PACT Global Study data on 305 patients from seven sites in Belgium shows that at one year, patients experienced positive outcomes based on both efficacy and safety measures, consistent with overall findings from the IN.PACT Global Study. In this patient subset, the low CD-TLR at one year (7.6 percent) was also consistent with the results in the complete cohort of patients in the IN.PACT Global Study (7.5 percent). Results of the primary safety endpoint in the Belgium cohort were also consistent with results from the full study, with 90.6 percent of patients achieving positive outcomes. Data were presented at the Leipzig Interventional Course (LINC) 2017 conference.